This September, Pralsetinib (GAVRETO) received approval by FDA for the treatment of adults with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC). RET-activating fusions and mutations are key disease drivers in many cancer types, including NSCLC and medullary thyroid cancer (MTC). GAVRETO inhibits primary RET fusions and mutations that cause cancer in subsets of patients, as well as secondary RET mutations predicted to drive resistance to treatment.
Pralsetinib contains cyclohexyl pyrimidine moiety in its backbone. We have made a set of Building Blocks, which contain such part – the perfect start for your research!